Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index; 4 of the 5 sources its claims cite were checked for support.
Abstract
Background Clostridioides difficile infection (CDI) is a significant healthcare-associated infection. Probiotics have been proposed as a preventive strategy. This umbrella review synthesizes evidence from meta-analyses on the efficacy of probiotics in preventing CDI. Methods A comprehensive systematic search was conducted in PubMed, Scopus, Web of Science, Embase, and the Cochrane Library up to December 2025. To manage overlap, a single primary systematic review was selected per outcome. The methodological quality of included reviews was assessed using AMSTAR-2, and the certainty of evidence was graded. Pooled effect sizes were calculated using a random-effects model. Results Sixteen systematic reviews and meta-analyses were included. The pooled relative risk (RR) from primary reviews indicated that probiotics significantly reduced CDI risk (RR = 0.37; 95% CI: 0.32 to 0.42; I 2 = 0%). Multi-strain probiotics and formulations containing Saccharomyces boulardii showed significant benefits. The quality of evidence ranged from moderate to low, and overlap among primary studies was minimal (Corrected Covered Area = 15%). Conclusion Probiotic supplementation is associated with a reduced risk of CDI. However, given the variable methodological quality of the underlying evidence, these findings should be interpreted with caution. Population-specific and strain-specific effects require further investigation.
Overview
CoChat Summary
## TL;DR
This umbrella review found that probiotic supplementation was associated with a lower risk of Clostridioides difficile infection (CDI), with the main pooled estimate showing RR = 0.37 (95% CI 0.32 to 0.42). The strongest signals were for Saccharomyces boulardii and multi-strain formulations, but the underlying evidence was mostly low quality.
## Key findings
- Sixteen systematic reviews and meta-analyses were included; overlap among primary studies was minimal (Corrected Covered Area = 15%).
- In the primary RR synthesis based on seven meta-analyses, probiotics reduced CDI risk by 63%: RR = 0.37 (95% CI 0.32 to 0.42; p < 0.001; I2 = 0%).
- Subgroup results showed significant benefits for Saccharomyces boulardii (RR = 0.38; 95% CI 0.27 to 0.53; 3 reviews) and multi-strain formulations (RR = 0.34; 95% CI 0.24 to 0.49; 4 reviews).
- The OR synthesis from four meta-analyses also favored probiotics: OR = 0.54 (95% CI 0.32 to 0.89; p = 0.001), though heterogeneity was substantial (I2 = 74.9%).
## Methods
- Umbrella review of systematic reviews and meta-analyses, conducted per PRISMA 2020 and registered in PROSPERO (CRD420251062730).
- Searched PubMed, Scopus, Web of Science, Embase, and the Cochrane Library from inception through December 2025; English-language studies only.
- Included systematic reviews/meta-analyses of probiotics for CDI prevention that reported effect sizes and confidence intervals; quality assessed with AMSTAR-2, certainty with GRADE, overlap with CCA, and pooled effects estimated using random-effects REML models.
## Limitations
- Stated by the paper: 11 of 16 included reviews were rated “critically low” on AMSTAR-2; overall certainty of evidence was “low” by GRADE.
- Stated by the paper: robust quantitative analyses could not be performed for all pre-specified strata, including specific dosage and patient sub-populations, because of inconsistent reporting in the source reviews.
- Evident from the text: the evidence combines diverse probiotic strains and populations, and some results rely on only a few meta-analyses, which limits strain-specific and population-specific conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
3 Valid · 0 Not valid · 0 Not checked · 29 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“While most previous meta-analyses align with our pooled result, one review by Dabrowski et al. reported no significant benefit for patients exposed to antibiotics (19, 39, 40).”
§ Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis > Discussion
What the sources say
- Supportedcites [19] Dabrowski, 2023, Use of probiotics in the prevention of Clostridioides difficile infections during antibiotic exposure: a systematic review and Meta-analysis, medRxiv source
The Methods (section 2.5; page unavailable) say the meta-analysis calculated pooled relative risk and 95% confidence intervals. The pooled estimate in section 3.8.1 is 0.68 (95% CI 0.31–1.06); because that interval includes 1, it does not establish a statistically significant overall benefit. The paper nevertheless describes the direction of the effect as positive. (LLM, conf=0.88)
- Could not verifycites [39] Chou, 2017, Immunomodulatory effects of Saccharomyces cerevisiae fermentation product supplementation on immune gene expression and lymphocyte distribution in immune organs in broilers, Front. Vet. Sci. sourceExperimental — accuracy not yet measured
The Introduction discusses yeast fermentation product supplementation and immune effects in broilers, not probiotic outcomes in patients. Searches for Dabrowski, antibiotic-exposed patients, and a probiotic review found no passage in our copy addressing the claimed lack of benefit. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [40] Awais, 2019, Immunomodulatory and ameliorative effects of Lactobacillus and Saccharomyces based probiotics on pathological effects of eimeriasis in broilers, Microb Pathog source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our subgroup analysis showed that, probiotics are effective in preventing CDI in studies less than 5,000 participants.”
§ Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis > Results > Probiotics supplementation in prevention of CDI based on relative risk analysis
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Significant reductions in CDI risk were observed for Saccharomyces boulardii (RR = 0.38; 95% CI: 0.27 to 0.53; 3 reviews) and multi-strain formulations (RR = 0.34; 95% CI: 0.24 to 0.49; 4 reviews).”
- Also stated in: § Results · plain
“Multi-strain probiotics and formulations containing Saccharomyces boulardii showed significant benefits.”
§ Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis > Results > Probiotics supplementation in prevention of CDI based on relative risk analysis
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The pooled relative risk (RR) from primary reviews indicated that probiotics significantly reduced CDI risk (RR = 0.37; 95% CI: 0.32 to 0.42; I2 = 0%).”
- Also stated in: § Probiotics supplementation in prevention of CDI based on relative risk analysis · plain
“The primary pooled estimate, derived from seven meta-analyses reporting RR, indicated that probiotic supplementation significantly reduced the risk of CDI by 63% (RR = 0.37; 95% CI: 0.32 to 0.42; p < 0.001) with no statistical heterogeneity (I2 = 0%) (Figure 2).”
- Also stated in: § Conclusion · hedged
“This umbrella review of systematic reviews and meta-analyses suggests that probiotic supplementation may be associated with a reduced risk of CDI, as indicated by both RR and OR estimates.”
§ Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Probiotics supplementation in prevention of CDI based on relative risk analysis · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Significant reductions in CDI risk were observed for Saccharomyces boulardii (RR = 0.38; 95% CI: 0.27 to 0.53; 3 reviews) and multi-strain formulations (RR = 0.34; 95% CI: 0.24 to 0.49; 4 reviews).”
- Also stated in: § Results · plain
“Multi-strain probiotics and formulations containing Saccharomyces boulardii showed significant benefits.”
§ Efficacy of probiotic supplementation in preventing Clostridioides difficile infection: an umbrella review of systematic reviews and meta-analysis > Results > Probiotics supplementation in prevention of CDI based on relative risk analysis
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
11 more claims
Create a free account to see all 32 claims and every source verdict.
- Probably not a substantial claim. 12
- It may state two separate claims as one. 4
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048 · cited 1×
“The pooled ES and its associated 95% CI were estimated using random-effects models performed using restricted maximum likelihood (REML) model (16).”
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Shea, B. J., Reeves, B. C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., Kristjansson, E., et al. (2017) · BMJ · doi:10.1136/bmj.j4008 · Cited by 10,636 · cited 1×
“The Measurement Tool to Assess Systematic Reviews (AMSTAR)2 questionnaire was used to qualify the included studies by two independent researchers (14), which consists of 16 items rated as “yes,” “no,” or “not applicable.”
Probiotics, gut microbiota, and their influence on host health and disease
Sánchez, B., Delgado, S., Blanco‐Míguez, A., Lourenço, A., Gueimonde, M., & Margolles, A. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600240 · Cited by 1,104
Potential Uses of Probiotics in Clinical Practice
Reid, G., Jass, J., Sebulsky, M. T., & McCormick, J. K. (2003) · Clinical Microbiology Reviews · doi:10.1128/cmr.16.4.658-672.2003 · Cited by 912 · cited 1×
“The World Health Organization (WHO) defines probiotics as live microorganisms that confer health benefits when administered in adequate amounts (9, 10).”
Probiotics Regulate Gut Microbiota: An Effective Method to Improve Immunity
Wang, X., Zhang, P., & Zhang, X. (2021) · Molecules · doi:10.3390/molecules26196076 · Cited by 529 · cited 1×
“Probiotics are thought to compete with pathogens, helping to maintain gut microbiota balance, promote gut barrier function, preserve intestinal integrity, and modulate immune responses (11, 12).”
Johnston, B. C., Ma, S. S. Y., Goldenberg, J. Z., Thorlund, K., Vandvik, P. O., Loeb, M., & Guyatt, G. H. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00563 · Cited by 367 · cited 1×
“For the primary outcome of CDI prevention based on RR, the review by Johnston et al. (2012) was selected as the primary synthesis due to its comprehensive scope and methodological rigor.”
How do intestinal probiotics restore the intestinal barrier?
Gou, H.-Z., Zhang, Y.-L., Ren, L.-F., Li, Z.-J., & Zhang, L. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.929346 · Cited by 305 · cited 2×
“Probiotics are thought to compete with pathogens, helping to maintain gut microbiota balance, promote gut barrier function, preserve intestinal integrity, and modulate immune responses (11, 12).”
Gupta, V, & Garg, R. (2009) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.53201 · Cited by 283
Shen, N. T., Maw, A., Tmanova, L. L., Pino, A., Ancy, K., Crawford, C. V., Simon, M. S., & Evans, A. T. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.02.003 · Cited by 273
Finn, E., Andersson, F. L., & Madin-Warburton, M. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06147-y · Cited by 207
The burden of CDI in the United States: a multifactorial challenge
Feuerstadt, P., Theriault, N., & Tillotson, G. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08096-0 · Cited by 181
Chamberlain, R., & Lau, C. (2016) · International Journal of General Medicine · doi:10.2147/ijgm.s98280 · Cited by 177
Goodman, C., Keating, G., Georgousopoulou, E., Hespe, C., & Levett, K. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043054 · Cited by 163
Guo, S., Gillingham, T., Guo, Y., Meng, D., Zhu, W., Walker, W. A., & Ganguli, K. (2017) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000001310 · Cited by 129 · cited 1×
“Synergistic effects may arise from the combined actions of different strains: Saccharomyces is noted for immunomodulation, Lactobacillus for restoring microbial balance (41, 42), and Bifid bacterium for supporting barrier function (43).”
McFarland, L. (2015) · Antibiotics · doi:10.3390/antibiotics4020160 · Cited by 109 · cited 1×
“Eleven of the 16 reviews were rated as having “critically low” overall confidence, primarily due to short-comings in protocol registration, risk of bias assessment, and reporting of excluded studies (17–19, 21–23, 25–28, 31).”
Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection
Webb, B. J., Subramanian, A., Lopansri, B., Goodman, B., Jones, P. B., Ferraro, J., Stenehjem, E., & Brown, S. M. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02169-19 · Cited by 99
Salari (2012) · doi:10.2174/187152812798889394 · Cited by 78
Vernaya, M., McAdam, J., & Hampton, M. D. (2017) · JBI Database of Systematic Reviews and Implementation Reports · doi:10.11124/jbisrir-2016-003234 · Cited by 51
Probiotics: insights and new opportunities for Clostridioides difficile intervention
Pal, R., Athamneh, A. I. M., Deshpande, R., Ramirez, J. A. R., Adu, K. T., Muthuirulan, P., Pawar, S., Biazzo, M., Apidianakis, Y., Sundekilde, U. K., et al. (2022) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2022.2072705 · Cited by 50 · cited 1×
“Also, they are effective in strengthening intestinal barrier integrity (12), and modulating immune responses (36–38).”
Johnston, B. C., Lytvyn, L., Lo, C. K.-F., Allen, S. J., Wang, D., Szajewska, H., Miller, M., Ehrhardt, S., Sampalis, J., Duman, D. G., et al. (2018) · Infection Control & Hospital Epidemiology · doi:10.1017/ice.2018.84 · Cited by 50 · cited 1×
“Eleven of the 16 reviews were rated as having “critically low” overall confidence, primarily due to short-comings in protocol registration, risk of bias assessment, and reporting of excluded studies (17–19, 21–23, 25–28, 31).”
Faghfouri, A. H., Afrakoti, L. G. M. P., Kavyani, Z., Nogourani, Z. S., Musazadeh, V., Jafarlou, M., & Dehghan, P. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01332-8 · Cited by 49 · cited 1×
“Also, they are effective in strengthening intestinal barrier integrity (12), and modulating immune responses (36–38).”
Avadhani, A., & Miley, H. (2011) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2011.00617.x · Cited by 47
Awais, M. M., Jamal, M. A., Akhtar, M., Hameed, M. R., Anwar, M. I., & Ullah, M. I. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2018.10.038 · Cited by 46 · cited 1×
“While most previous meta-analyses align with our pooled result, one review by Dabrowski et al. reported no significant benefit for patients exposed to antibiotics (19, 39, 40).”
Musazadeh, V., Anilou, M. M., Vajdi, M., Karimi, A., Ahrabi, S. S., & Dehghan, P. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1121541 · Cited by 44
Ma, Y., Yang, J. Y., Peng, X., Xiao, K. Y., Xu, Q., & Wang, C. (2020) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12839 · Cited by 44
Linninge, C., Xu, J., Bahl, M. I., Ahrné, S., & Molin, G. (2019) · Beneficial Microbes · doi:10.3920/bm2018.0074 · Cited by 40 · cited 1×
“Synergistic effects may arise from the combined actions of different strains: Saccharomyces is noted for immunomodulation, Lactobacillus for restoring microbial balance (41, 42), and Bifid bacterium for supporting barrier function (43).”
Zhou, F., Wu, S., Klena, J. D., & Huang, H. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-014-2132-9 · Cited by 38
Chou, W. K., Park, J., Carey, J. B., McIntyre, D. R., & Berghman, L. R. (2017) · Frontiers in Veterinary Science · doi:10.3389/fvets.2017.00037 · Cited by 36 · cited 1×
“While most previous meta-analyses align with our pooled result, one review by Dabrowski et al. reported no significant benefit for patients exposed to antibiotics (19, 39, 40).”
Sinclair, A., Xie, X., Saab, L., & Dendukuri, N. (2016) · CMAJ Open · doi:10.9778/cmajo.20160087 · Cited by 33 · cited 1×
“The probiotic Lactobacillus was associated with a 75% reduction in the risk of CDI-associated diarrhea compared with placebo (RR = 0.25; 95% CI: 0.08 to 0.47) (33).”
InfluentialMcFarland, L. V. (2013) · World Journal of Meta-Analysis · doi:10.13105/wjma.v1.i3.102 · Cited by 33
Song, X., Song, W., Cui, L., Duong, T. Q., Pandy, R., Liu, H., Zhou, Q., Sun, J., Yan-li, L., & Li, T. (2024) · Diagnostics · doi:10.3390/diagnostics14111168 · Cited by 24
The divergent restoration effects of Lactobacillus strains in antibiotic-induced dysbiosis
Shi, Y., Kellingray, L., Gall, G. L., Zhao, J., Zhang, H., Narbad, A., Zhai, Q., & Chen, W. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.10.011 · Cited by 22 · cited 1×
“Synergistic effects may arise from the combined actions of different strains: Saccharomyces is noted for immunomodulation, Lactobacillus for restoring microbial balance (41, 42), and Bifid bacterium for supporting barrier function (43).”
Self-citationYang, J., Meng, L., Li, Y., & Huang, H. (2023) · Food & Function · doi:10.1039/d3fo02110f · Cited by 21 · cited 1×
“Probiotics are more potent to restore the gut microbiota balance which may contribute to the CDI (34, 35).”
The mechanisms and safety of probiotics against toxigenic clostridium difficile
Liu, D., Zeng, L., Yan, Z., Jia, J., Gao, J. X., & Wei, Y. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1778464 · Cited by 18
Barbosa, M. L. L., Albano, M. O., Martins, C. D. S., Warren, C. A., & Brito, G. A. D. C. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1219225 · Cited by 14 · cited 1×
“Probiotics are more potent to restore the gut microbiota balance which may contribute to the CDI (34, 35).”
Kim, B., Kim, J., & Pai, H. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e407 · Cited by 11 · cited 1×
“Antibiotic treatment disrupts the gut microbiota, facilitating the development of CDI (4).”
Wanyama, H., Akhtar, T. S., & Abbas, S. (2025) · Gastroenterology Review · doi:10.5114/pg.2025.148486 · Cited by 8 · cited 1×
“However, another meta-analysis reported that mixed probiotic formulations reduced the incidence of CDI-associated diarrhea by approximately 40% in adult patients (RR = 0.60; 95% CI: 0.43 to 0.83) (32).”
InfluentialTariq, R., Tahir, M. W., Hayat, M., Pardi, D. S., & Khanna, S. (2022) · JOURNAL OF GASTROINTESTINAL INFECTIONS · doi:10.1055/s-0043-1760738 · Cited by 7
Almutawif, Y. A., Najim, M. A., & Khan, N. U. (2025) · Infection · doi:10.1007/s15010-025-02580-2 · Cited by 4
Research works printed but not linked: 1
- Pattani, 2013, Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systematic review and meta-analysis, Open Med., 7, e56
Cited by
Probiotics unveiled: bridging general health benefits to the era of precision medicine
Ullah, M., Rizwan, M., Waheed, M. I., Alam, M. S., Jan, S. U., Raza, A., Shahid, M. F., Andoh, V., & Chen, Y. (2026) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-026-05143-1
Guo, H., Zhang, C., Wang, R., Yang, Y., Wang, G., Cui, S., Lu, W., Yang, B., Lyu, X., Tian, P., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2728330
“135,136 Several mechanisms have been proposed, including enhancing colonization resistance, 137 attenuating C. difficile virulence, 138 and reducing the ecological space of pathogens following antibiotic-associated dysbiosis.”
Präbiotika, Probiotika, Nahrungsmittelunverträglichkeiten, Ernährung bei Reizdarmsyndrom
Scheppach, W. M., & Andresen, V. (2026) · De Gruyter eBooks · doi:10.1515/9783112213056-014
Metadata
- Authors
- Chen, W., Pan, X., Ji, J., Wu, Z., & Lin, X.
- Affiliations
- Zhejiang Chinese Medical University (CN)
- Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University (CN)
- Department of Rehabilitation, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine
- Corresponding author
- Ji, Jing
- Wu, Zhenhua
- Lin, Xinxin
- Venue
- Frontiers in Nutrition
- Publisher
- Frontiers Media SA
- Published
- 2026-03-09
- Volume
- 13
- Pages
- 1699223-1699223
- ISSN
- 2296-861X (ISSN-L)
- PMC
- PMC13006325
- OpenAlex
- W7134243021
- Cited by
- 3
- References
- 41
- Citations by year
- 2026: 3
- FWCI
- 4.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Nutrition (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Science and Technology Plan Project of Wenzhou, China
- Natural Science Foundation of Zhejiang Province (LQ24H270001)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Keywords
- probiotics, Clostridium difficile infection, infection control, nosocomial infections, Saccharomyces boulardii, multi-strain probiotics, probiotic formulation, probiotic supplementation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.